FATE THERAPEUTICS INC Contracts & Agreements

Amendment No.4 to Collaboration and Option Agreement by and between the Registrant and Ono Pharmaceutical Co., Ltd, dated August 28, 2024 (Filed With SEC on November 12, 2024)

Amended and Restated Form of Indemnification Agreement (Filed With SEC on August 30, 2024)

Amended and Restated 2022 Stock Option and Incentive Plan and form agreements thereunder (Filed With SEC on June 7, 2024)

Underwriting Agreement, dated as of March 19, 2024, among Fate Therapeutics, Inc., BofA Securities, Inc., Jefferies LLC and Leerink Partners LLC, as representatives of the... (Filed With SEC on March 21, 2024)

Form of Pre-Funded Warrant (Filed With SEC on March 21, 2024)

Securities Purchase Agreement, dated as of March 19, 2024, between Fate Therapeutics, Inc. and RedCo II Master Fund, L.P (Filed With SEC on March 21, 2024)

Amendment 03 to Collaboration and Option Agreement, dated November 30, 2023, by and between the Registrant and Ono Pharmaceutical Co. Ltd (Filed With SEC on February 26, 2024)

Exclusive License Agreement, dated April 17, 2020, by an between the Registrant and Baylor College of Medicine (Filed With SEC on February 26, 2024)

Description of Securities (Filed With SEC on November 8, 2023)

Amended and Restated Non-Employee Director Compensation Policy (Filed With SEC on August 8, 2023)

Letter Agreement, dated November 7, 2022, by and between Fate Therapeutics, Inc. and Ono Pharmaceutical Co., Ltd (Filed With SEC on November 7, 2022)

Amendment 01 to Collaboration and Option Agreement, dated June 28, 2022, by and between the Registrant and Ono Pharmaceutical Co. Ltd (Filed With SEC on August 3, 2022)

License Agreement, dated April 9, 2020, by and between the Registrant and Dana-Farber Cancer Institute, Inc (Filed With SEC on February 28, 2022)

Open Market Sale AgreementSM dated November 4, 2021 by and between Fate Therapeutics, Inc. and Jefferies LLC (Filed With SEC on November 4, 2021)

Amended and Restated Non-Employee Director Compensation Policy (Filed With SEC on August 4, 2021)

Description of Securities (Filed With SEC on February 24, 2021)

Amended and Restated 2013 Stock Option and Incentive Plan and forms of agreements thereunder (Filed With SEC on February 24, 2021)

Amended and Restated Non-Employee Director Compensation Policy (Filed With SEC on February 24, 2021)

Fate Therapeutics, Inc. Amended and Restated Inducement Equity Plan (Filed With SEC on February 24, 2021)

Forms of Stock Option Agreement under Fate Therapeutics, Inc. Inducement Equity Plan (Filed With SEC on February 24, 2021)

Forms of Restricted Stock Unit Award Agreement under Fate Therapeutics, Inc. Inducement Equity Plan (Filed With SEC on February 24, 2021)

Whitehead Institute for Biomedical Research Exclusive Patent License Agreement between the Registrant and the Whitehead Institute for Biomedical Research, dated as of February 24,... (Filed With SEC on February 24, 2021)

License Agreement between the Registrant and The Scripps Research Institute, dated as of July 13, 2009 (Filed With SEC on February 24, 2021)

License Agreement between the Registrant and The Scripps Research Institute, dated as of May 25, 2010 (Filed With SEC on February 24, 2021)

License Agreement between the Registrant and The Scripps Research Institute, dated as of August 24, 2010 (Filed With SEC on February 24, 2021)

Letter Agreement, dated December 4, 2020, by and between the Registrant and Ono Pharmaceutical Co., Ltd (Filed With SEC on February 24, 2021)

Patent License Agreement by and between the Registrant and Max-Delbrck-Centrum fr Molekulare Medizin in der Helmholtz-Gemeinschaft, dated August 30, 2019 (Filed With SEC on February 24, 2021)

Underwriting Agreement, dated January 5, 2021 (Filed With SEC on January 8, 2021)

Form of Pre-Funded Warrant (Filed With SEC on January 8, 2021)

Offer Letter between the Company and Edward J. Dulac III, dated as of May 20, 2020 (Filed With SEC on August 19, 2020)

Underwriting Agreement, dated June 8, 2020 (Filed With SEC on June 10, 2020)

Description of Securities (Filed With SEC on March 2, 2020)

Amended and Restated Non-Employee Director Compensation Policy (Filed With SEC on March 2, 2020)

Fate Therapeutics, Inc. Inducement Equity Plan (Filed With SEC on March 2, 2020)

Lease Agreement by and between the Registrant and Scripps Summit Investments LLC, dated January 7, 2020 (Filed With SEC on March 2, 2020)

Underwriting Agreement, dated September 11, 2019 (Filed With SEC on September 13, 2019)

Amended and Restated Non-Employee Director Compensation Policy (Filed With SEC on March 5, 2019)

Fate Therapeutics, Inc. Inducement Equity Plan (Filed With SEC on March 5, 2019)

Offer Letter by and between the Registrant and Cindy R. Tahl, dated October 23, 2009 (Filed With SEC on March 5, 2019)

Offer Letter by and between the Registrant and Bahram Valamehr, dated November 23, 2009 (Filed With SEC on March 5, 2019)

Sales Agreement dated November 21, 2018 by and between Fate Therapeutics, Inc. and Leerink Partners LLC (Filed With SEC on November 21, 2018)

Exclusive License Agreement by and between the Registrant and The J. David Gladstone Institutes, dated September 11, 2018 (Filed With SEC on November 1, 2018)

Underwriting Agreement, dated September 20, 2018 (Filed With SEC on September 21, 2018)

Sixth Amendment to the Lease Agreement by and between the Registrant and ARE-3535/3565 General Atomics Court, dated May 31, 2018 (Filed With SEC on August 6, 2018)

Amended and Restated Exclusive License Agreement by and between the Registrant and Memorial Sloan Kettering Cancer Center, dated May 15, 2018 (Filed With SEC on August 6, 2018)

Employment Offer Letter by and between the Registrant and Chris M. Storgard, MD, dated April 27, 2016 (Filed With SEC on May 10, 2018)

Amended and Restated Employment Agreement by and between the Registrant and Scott Wolchko, dated January 14, 2018 (Filed With SEC on March 5, 2018)

Fate Therapeutics, Inc. Inducement Equity Plan (Filed With SEC on March 5, 2018)

Severance and Change in Control Policy (Filed With SEC on March 5, 2018)

Underwriting Agreement, dated December 12, 2017 (Filed With SEC on December 14, 2017)

Warrant to Purchase Common Stock issued to Silicon Valley Bank on July 14, 2017 (Filed With SEC on August 14, 2017)

First Amendment to Amended and Restated Loan and Security Agreement, by and between the Registrant and Silicon Valley Bank, dated July 14, 2017 (Filed With SEC on August 14, 2017)

FATE THERAPEUTICS, INC. AMENDED AND RESTATED 2013 STOCK OPTION AND INCENTIVE PLAN (Filed With SEC on May 8, 2017)

SECURITIES PURCHASE AGREEMENT (Filed With SEC on November 22, 2016)

REGISTRATION RIGHTS AGREEMENT (Filed With SEC on November 22, 2016)

FATE THERAPEUTICS, INC. AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY (Filed With SEC on August 8, 2016)

FIFTH AMENDMENT TO LEASE AGREEMENT (Filed With SEC on August 8, 2016)

SECURITIES PURCHASE AGREEMENT (Filed With SEC on August 8, 2016)

REGISTRATION RIGHTS AGREEMENT (Filed With SEC on August 8, 2016)

EMPLOYMENT AGREEMENT (Filed With SEC on March 3, 2016)

THIRD AMENDMENT TO LEASE AGREEMENT (Filed With SEC on March 3, 2016)

FOURTH AMENDMENT TO LEASE (Filed With SEC on March 3, 2016)

SUBLEASE (Filed With SEC on March 3, 2016)

STOCK PURCHASE AGREEMENT (Filed With SEC on August 5, 2015)

COLLABORATION AND LICENSE AGREEMENT (Filed With SEC on August 5, 2015)

FATE THERAPEUTICS, INC. AMENDMENT TO AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT (Filed With SEC on August 5, 2015)

6,000,000 Shares Fate Therapeutics, Inc. COMMON STOCK, PAR VALUE $0.001 PER SHARE UNDERWRITING AGREEMENT May 20, 2015 (Filed With SEC on May 21, 2015)

WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH and FATE THERAPEUTICS, INC. EXCLUSIVE PATENT LICENSE AGREEMENT (Filed With SEC on March 12, 2015)

LICENSE AGREEMENT by and between THE SCRIPPS RESEARCH INSTITUTE, a California nonprofit public benefit corporation and FATE THERAPEUTICS, INC., a Delaware corporation (Filed With SEC on March 12, 2015)

LICENSE AGREEMENT by and between THE SCRIPPS RESEARCH INSTITUTE, a California nonprofit public benefit corporation and FATE THERAPEUTICS, INC. a Delaware corporation 1 (Filed With SEC on March 12, 2015)

LICENSE AGREEMENT by and between THE SCRIPPS RESEARCH INSTITUTE, a California nonprofit public benefit corporation and FATE THERAPEUTICS, INC. a Delaware corporation (Filed With SEC on March 12, 2015)

FATE THERAPEUTICS, INC. AMENDED AND RESTATED SENIOR EXECUTIVE INCENTIVE BONUS PLAN (Filed With SEC on January 7, 2015)

UNRESTRICTED STOCK AWARD AGREEMENT UNDER THE FATE THERAPEUTICS, INC. 2013 STOCK OPTION AND INCENTIVE PLAN (Filed With SEC on January 7, 2015)

AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT (Filed With SEC on August 5, 2014)

WARRANT TO PURCHASE COMMON STOCK (Filed With SEC on August 5, 2014)

FATE THERAPEUTICS, INC. SENIOR EXECUTIVE CASH INCENTIVE BONUS PLAN (Filed With SEC on January 10, 2014)

SECOND AMENDMENT TO LEASE AGREEMENT (Filed With SEC on September 30, 2013)

FATE THERAPEUTICS, INC. 2013 STOCK OPTION AND INCENTIVE PLAN (Filed With SEC on September 16, 2013)

FATE THERAPEUTICS, INC. 2013 EMPLOYEE STOCK PURCHASE PLAN (Filed With SEC on September 16, 2013)

[ ] Shares FATE THERAPEUTICS, INC. Common Stock UNDERWRITING AGREEMENT (Filed With SEC on September 3, 2013)

FATE THERAPEUTICS, INC. 2013 STOCK OPTION AND INCENTIVE PLAN (Filed With SEC on September 3, 2013)

FATE THERAPEUTICS, INC. 2013 EMPLOYEE STOCK PURCHASE PLAN (Filed With SEC on September 3, 2013)

Additional abbreviations may also be used though not in the above list. (Filed With SEC on August 29, 2013)

FATE THERAPEUTICS, INC. 2007 EQUITY INCENTIVE PLAN (Filed With SEC on August 29, 2013)

FATE THERAPEUTICS, INC. FORM OF [DIRECTOR][OFFICER] INDEMNIFICATIONAGREEMENT (Filed With SEC on August 29, 2013)

WARRANT TO PURCHASE STOCK (Filed With SEC on August 14, 2013)

FIRST AMENDMENT TO WARRANT TO PURCHASE STOCK DATED JANUARY 5, 2009 (Filed With SEC on August 14, 2013)

WARRANT TO PURCHASE STOCK (Filed With SEC on August 14, 2013)

FATETHERAPEUTICS, INC. CONVERTIBLE PROMISSORY NOTE (Filed With SEC on August 14, 2013)

FATE THERAPEUTICS, INC. CONVERTIBLE PROMISSORY NOTE (Filed With SEC on August 14, 2013)

FATE THERAPEUTICS, INC. 2007 EQUITY INCENTIVE PLAN (Filed With SEC on August 14, 2013)

FATE THERAPEUTICS, INC. (Filed With SEC on August 14, 2013)

CONSULTING AGREEMENT (Filed With SEC on August 14, 2013)

Fate Therapeutics, Inc. 3535 General Atomics Court, Suite 200 San Diego, CA 92121 (Filed With SEC on August 14, 2013)

EXCLUSIVE LICENSE AGREEMENT BETWEEN CHILDRENS MEDICAL CENTER CORPORATION AND FATETHERAPEUTICS, INC. (Filed With SEC on August 14, 2013)

EXCLUSIVE LICENSE AGREEMENT (Filed With SEC on August 14, 2013)

RESTATED LICENSE AGREEMENT (Filed With SEC on August 14, 2013)

First Amendment to Restated License Agreement (Filed With SEC on August 14, 2013)

Second Amendment to Restated License Agreement (Filed With SEC on August 14, 2013)

LEASE AGREEMENT (Filed With SEC on August 14, 2013)

FIRST AMENDMENT TO LEASE AGREEMENT (Filed With SEC on August 14, 2013)

LOAN AND SECURITY AGREEMENT (Filed With SEC on August 14, 2013)

AMENDMENT NO. 1 TO LOAN AND SECURITY AGREEMENT (Filed With SEC on August 14, 2013)

SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT (Filed With SEC on August 14, 2013)

FATE THERAPEUTICS, INC. AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT (Filed With SEC on August 14, 2013)

NOTE PURCHASE AGREEMENT (Filed With SEC on August 14, 2013)

Fate Therapeutics, Inc. 3535 General Atomics Court, Suite 200 San Diego, CA 92121 (Filed With SEC on August 14, 2013)

NOTE PURCHASE AGREEMENT (Filed With SEC on August 14, 2013)

Category

Industry

Companies

Contracts

FATE THERAPEUTICS INC Contracts & Agreements